Abstract
The evolutionary dynamics of cancerous cell populations in a model of Chronic Myeloid Leukemia (CML) is investigated in the presence of an intermittent targeted therapy. Cancer development and progression is modeled by simulating the stochastic evolution of initially healthy cells which can experience genetic mutations and modify their reproductive behavior, becoming leukemic clones. Front line therapy for the treatment of patients affected by CML is based on the administration of tyrosine kinase inhibitors, namely imatinib (Gleevec) or, more recently, dasatinib or nilotinib. Despite the fact that they represent the first example of a successful molecular targeted therapy, the development of resistance to these drugs is observed in a proportion of patients, especially those in advanced stages. In this study, we simulate an imatinib-like treatment of CML by modifying the fitness and the death rate of cancerous cells and describe the several scenarios in the evolutionary dynamics of white blood cells as a consequence of the efficacy of the different modeled therapies. The patient response to the therapy is investigated by simulating a drug administration following a continuous or pulsed time scheduling. A permanent disappearance of leukemic clones is achieved with a continuous therapy. This theoretical behavior is in a good agreement with that observed in previous clinical investigations. However, these findings demonstrate that an intermittent therapy could represent a valid alternative in patients with high risk of toxicity. A suitable tuned pulsed therapy can also reduce the probability of developing resistance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abbott LH, Michor F (2006) Mathematical models of targeted cancer therapy. Br J Cancer 95:1136–1141
André N, Pasquier E (2009) Response to “intermittent androgen blockade should be regarded as standard therapy in prostate cancer". Nat Clin Pract Oncol 6:E1
Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163a
Brumer Y, Michor F, Shakhnovich EI (2006) Genetic instability and the quasispecies model. J Theor Biol 241:216–222
Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, Lacombe F, Praloran V, Mahon FX (2007) Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a bim-dependant pathway modulated by cytokines. Cancer Biol Ther 6:912–919
Dingli D, Michor F (2006) Successful therapy must eradicate cancer stem cells. Stem Cells 24:2603–2610
Faber E, Naušová J, Jarošová M, Egorin MJ, Holzerová M, Rožmanová S, Marešová I, Divoký V, Indrák K (2006) Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. Leuk Lymphoma 47:1082–1090
Frank SA, Iwasa Y, Nowak M (2003) Patterns of cell division and the risk of cancer. Genetics 163:1527–1532
Garner AL, Lau YY, Jordan DW et al. (2006) Implications of a simple mathematical model to cancer cell population dynamics. Cell Prolif 39:15–28
Hochhaus A, La Rosée P (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18:1321–1331
Horn M, Loeffler M, Roeder I (2008) Mathematical modeling of genesis and treatment of chronic myeloid leukemia. Cells Tissues Organs 188:236–247
Ichimaru M, Ishimaru T, Mikami M, Yamada Y, Ohkita T (1981) Incidence of leukemia in a fixed cohort of atomic bomb survivors and controls, Hiroshima and Nagasaki, October 1950–December 1978. Technical Report no. 13-81. Hiroshima, Radiation Effects Research Foundation
Iwasa Y, Michor F, Nowak M (2004) Stochastic tunnels in evolutionary dynamics. Genetics 166:1571–1579
Jackson AL, Loeb LA (1998) The mutation rate and cancer. Genetics 148:1483–1490
Knudson AG (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157–170
Komarova NL, Wodarz D (2007) Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. Theor Popul Biol 72:523–538
Loeb LA, Essigmann JM et al.(2002) Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci 96:1492–1497
Martinelli G, Soverini S, Iacobucci I, Baccarani M (2009) Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy. Nat Clin Pract Oncol 6:68–69
Michor F, Nowak M, Frank SA, Iwasa Y (2003) Stochastic elimination of cancer cells. Proc R Soc Lond B 270:2017–2024
Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA (2005) Dynamics of chronic myeloid leukemia. Nature 435:1267–1270
Michor F, Nowak M, Iwasa Y (2006) Evolution of resistance to cancer therapy. Curr Pharm Des 12:261–271
Michor F (2007) Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells 25:1114–1118
Moran PAP (1962) The statistical processes of evolutionary theory. Oxford: Clarendon Press
Müller MC, Lahaye T, Hochhaus A (2002) Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells. Dtsch Med Wochenschr 127:2205–2207
Nowak MA, Komarova NL, Sengupta A, Jallepalli PV, Shih I, Vogelstein B, Lengauer C (2002) The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci 99:16226–16231
Pizzolato N, Valenti D, Persano Adorno D et al. (2009) Evolutionary dynamics of imatinib-treated leukemic cells by stochastic approach. Cent Eur J Phys 7:541–548
Rea D, Etienne G, Corm S, Cony-Makhoul P, Gardembas M, Legros L, Dubruille V, Hayette S, Mahon F-X, Cayuela J-M, Nicolini FE (2009) Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy. Leukemia 23:1193–1196
Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12:1181–1184
Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AMH (2008) Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 68:4518–4524
Seruga B, Tannock IF (2008) Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 5:574–576
Shah NP, Kantarjian HM, Kim D, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A (2008) Intermittent target Inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204–3212
Sokal JE, Baccarani M, Russo D, Tura S. (1988) Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25:49–61
Vigneri P, Wang JY (2001) Induction of apoptosis in chronic myelogenous leukemia cells throught nuclear entrapment of BCR–ABL tyrosine kinase. Nat Med 7:228–234
Weisberg E, Griffin JD (2001) Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drugs Resist Updat 4:22–28
Weisberg E, Griffin JD (2003) Resistance to imatinib (Glivec): update on clinical mechanisms. Drugs Resist Updat 6:231–238
Zhdanov VP (2008) Stochastic model of the formation of cancer metastases via cancer stem cells. Eur Biophys J 37:1329–1334
Acknowledgements
This study was partially supported by MIUR. N. P. wish to thank Prof. Clementina Caracciolo and Dr. Rita Barone of the Department of Hematology and Bone Marrow Transplant Unit, Palermo-Italy, for helpful discussions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pizzolato, N., Persano Adorno, D., Valenti, D. et al. Stochastic dynamics of leukemic cells under an intermittent targeted therapy. Theory Biosci. 130, 203–210 (2011). https://doi.org/10.1007/s12064-011-0127-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12064-011-0127-y